Core Viewpoint - Liaoning Chengda Co., Ltd. has successfully completed the repayment of its third short-term financing bond for the year 2024, which was issued at a total amount of 700 million RMB with a maturity of one year and an interest rate of 2.9% [1][1][1] Summary by Sections Financing Details - The company registered a short-term financing bond issuance limit of up to 2 billion RMB as approved in the 2021 annual shareholders' meeting [1] - The third short-term financing bond for 2024 was issued on September 26, 2024, amounting to 700 million RMB [1][1] - The bond had a face value price of 100 RMB per 100 RMB face value [1] Repayment Information - The third short-term financing bond matured on September 27, 2025, and the company has completed the repayment of both principal and interest [1][1][1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600739 证券简称：辽宁成大 公告编号：2025-075 辽宁成大股份有限公司 2025年第三次临时股东会决议公告 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 444 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 695,822,141 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 45.7081 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况 等。 本次会议由董事会提议召开，由董事长徐飚先生主持，以记名投票方式表决。 (一) 股东会召开的时间：2025 年 9 月 30 日 (二) 股东会召开的地点：公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 会议采用现场投票和网络投票相结合的方式进行。会议的召开、表决方式符合《公 司法》及《公司章程》的规 ...

辽宁恒信律师事务所 关于辽宁成大股份有限公司2025年第三次临时股东会的 法律意见书 致：辽宁成大股份有限公司 辽宁恒信律师事务所（以下简称"本所"）接受辽宁成大股份有限公司（以 下简称"公司"）的委托，指派张贞东律师、于璇聪律师（以下简称"本所律师"） 出席公司2025年第三次临时股东会（以下简称"本次股东会"），并对本次股东 会的合法性进行见证。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下 简称"《股东会规则》"）等有关法律、法规和规范性文件以及《辽宁成大股份 有限公司章程》（以下简称"《公司章程》"），本所律师审查了公司提供的如 下文件： 辽宁恒信律师事务所 法律意见书 1. 公司现行的《公司章程》； 2. 公司于2025年8月29日召开的第十一届董事会第六次会议的《董事会决 议》； 3. 公司于2025年8月30日刊登于《中国证券报》《上海证券报》《证券时报》 《证券日报》与上海证券交易所网站（http://www.sse.com.cn）的《辽宁成大股 份有限公司第十一届董事会第六次会议决议公告》；公司于2 ...

2025 年 9 月 30 日 2022 年 5 月 31 日，辽宁成大股份有限公司（以下简称"公司"）2021 年年 度股东大会审议通过了《关于注册短期融资券发行额度的议案》，公司向中国银 行间市场交易商协会申请注册金额不超过 20 亿元（含）人民币的短期融资券发 行额度。公司于 2024 年 9 月 26 日完成了 2024 年度第三期短期融资券的发行， 金额为人民币 7 亿元，期限为一年，票面利率为 2.9%，票面价格 100 元/百元面 值。 2024 年度第三期短期融资券已于 2025 年 9 月 27 日到期，公司已完成该期 短期融资券本息的兑付。 特此公告。 辽宁成大股份有限公司 关于 2024 年度第三期短期融资券到期兑付公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 辽宁成大股份有限公司董事会 证券代码：600739 证券简称：辽宁成大 公告编号：2025-074 ...

Market Overview - The biopharmaceutical sector increased by 0.78% on September 29, with Norseland leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Top Gainers in Biopharmaceutical Sector - Norseland (Code: 430047) closed at 24.80, up 6.57% with a trading volume of 68,400 shares and a transaction value of 169 million yuan [1] - Liaoning Chengda (Code: 600739) closed at 12.54, up 4.85% with a trading volume of 311,400 shares and a transaction value of 384 million yuan [1] - Rongchang Biotech (Code: 688331) closed at 110.00, up 4.76% with a trading volume of 83,500 shares and a transaction value of 900 million yuan [1] Top Losers in Biopharmaceutical Sector - Kanghua Biotech (Code: 300841) closed at 75.47, down 2.34% with a trading volume of 40,800 shares and a transaction value of 307 million yuan [2] - Baipusais (Code: 301080) closed at 58.51, down 2.32% with a trading volume of 20,000 shares and a transaction value of 117 million yuan [2] - Rili Pharmaceutical (Code: 603087) closed at 76.37, down 2.18% with a trading volume of 120,740 shares and a transaction value of 1.573 billion yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 154 million yuan from institutional investors, while retail investors saw a net inflow of 1.47 billion yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2][3] Individual Stock Capital Flow - Liaoning Chengda saw a net outflow of 52.59 million yuan from institutional investors, while retail investors had a net outflow of 40.07 million yuan [3] - Kanghua Biotech had a net inflow of 26.12 million yuan from institutional investors, but a net outflow of 47.70 million yuan from retail investors [3] - Three Life National Health (Code: 688336) had a net inflow of 23.37 million yuan from institutional investors, with retail investors also experiencing a net outflow [3]

Core Points - The company has successfully issued a short-term financing bond with a total amount of 800 million RMB [1] - The registered amount for short-term financing bonds is 3 billion RMB, valid for two years [1] - The funds raised will primarily be used to repay interest-bearing debts [1] Summary by Sections - **Issuance Details** - The company issued 800 million RMB of short-term financing bonds on September 23, 2025 [1] - The funds were fully received on September 24, 2025 [1] - **Approval and Registration** - The issuance was approved during the company's second extraordinary general meeting on October 23, 2024 [1] - The China Interbank Market Dealers Association issued a registration acceptance notice for the bond [1] - **Underwriting** - Dalian Bank Co., Ltd. acted as the lead underwriter for the bond issuance [1]

Core Points - Liaoning Chengda announced the approval of a short-term financing bond issuance limit of 3 billion yuan [2] - The registration notice for the bond issuance has been accepted by the China Interbank Market Dealers Association, valid for 2 years [2] - The company successfully issued 800 million yuan of short-term financing bonds on September 23, 2025, with funds fully received on September 24, 2025, primarily for repaying interest-bearing debts [2]

证券代码：600739 证券简称：辽宁成大 公告编号：2025－073 辽宁成大股份有限公司 2025 年度第二期短期融资券发行结果公告 公 司 本 次 短 期 融 资 券 发 行 相 关 文 件 详 见 上 海 清 算 所 网 站 （http://www.shclearing.com/）。 特此公告。 辽宁成大股份有限公司董事会 2025 年 9 月 26 日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2024 年 10 月 23 日，辽宁成大股份有限公司（以下简称"公司"）2024 年第二次 临时股东会审议通过了《关于注册短期融资券发行额度的议案》。中国银行间市场交 易商协会已签发《接受注册通知书》（中市协注[2025]CP68 号），接受公司短期融资券 注册，注册金额为 30 亿元，注册额度自该通知书落款之日起 2 年内有效，由大连银 行股份有限公司主承销。 公司于 2025 年 9 月 23 日在全国银行间市场发行规模为 8 亿元人民币的辽宁成大 股份有限公司 2025 年度第二期短期融资券，募集资金已于 2 ...

Core Points - The company received a no-objection letter from the Shenzhen Stock Exchange regarding the non-public issuance of exchangeable bonds by its major shareholder, Liaoning Chengda Co., Ltd. [1] - Liaoning Chengda plans to issue exchangeable bonds with a total face value of up to 2.8 billion RMB, which is confirmed to meet the listing conditions of the Shenzhen Stock Exchange [1] - The no-objection letter is valid for 12 months from the date of issuance [1] Shareholding Structure - As of the announcement date, Liaoning Chengda and its concerted parties hold a total of 1,366,927,688 shares of the company, accounting for 17.97% of the total share capital [2] - The issuance of the exchangeable bonds will not lead to significant changes in the company's equity structure [2] - The company will disclose further developments regarding the non-public issuance of exchangeable bonds in accordance with regulatory requirements [2]

Core Viewpoint - Liaoning Chengda Co., Ltd. has received a no-objection letter from the Shenzhen Stock Exchange regarding its non-public issuance of exchangeable bonds, confirming that the issuance meets the listing conditions [1] Group 1: Stock Performance - As of September 18, 2025, Liaoning Chengda's stock closed at 11.97 yuan, down 2.84% from the previous trading day, with a total market capitalization of 18.311 billion yuan [1] - The stock opened at 12.31 yuan, reached a high of 12.31 yuan, and a low of 11.88 yuan, with a trading volume of 213 million yuan and a turnover rate of 1.15% [1] Group 2: Bond Issuance - The company plans to issue exchangeable bonds with a reduced scale of no more than 2.8 billion yuan, down from the previously approved 5 billion yuan [1] - The no-objection letter confirms that the application for the issuance of exchangeable bonds with a face value of up to 2.8 billion yuan is compliant with the listing conditions [1] - The company must submit the application for listing transfer within twelve months from the issuance of the no-objection letter, or it will automatically expire [1]